Regarding the correlation of SOX30 with clinicopathological features in cancers, it has been presented that elevated SOX30 expression is associated with deficient LYN metastasis and lower TNM stage in lung cancer patients (10); a negative association has been found between SOX30 and TNM stage in bladder cancer patients (12); moreover, SOX30 is also negatively associated with tumor size in hepatocellular carcinoma patients (7). This evidence concerns the gene LYN and urinary bladder cancer.